dc.contributor.author | Ozyurek, Hamit | |
dc.contributor.author | Turker, Hande | |
dc.contributor.author | Akbalik, Mehtap | |
dc.contributor.author | Bayrak, Ayse Oytun | |
dc.contributor.author | Ince, Hulya | |
dc.contributor.author | Duru, Feride | |
dc.date.accessioned | 2020-06-21T15:24:33Z | |
dc.date.available | 2020-06-21T15:24:33Z | |
dc.date.issued | 2007 | |
dc.identifier.issn | 0888-0018 | |
dc.identifier.uri | https://doi.org/10.1080/08880010701451327 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12712/20265 | |
dc.description | WOS: 000251931700016 | en_US |
dc.description | PubMed: 17710662 | en_US |
dc.description.abstract | Vincristine is a commonly used antineoplastic drug and frequently causes neurotoxicity. Here the authors report a 4-year-old boy with acute lymphoblastic leukemia in whom vincristine-induced peripheral and cranial neuropathy developed during remission induction therapy. The patient seemed to benefit from pyridoxine and pyridostigmine therapy greatly and this therapy is recommended in patients with severe vincristine-induced neuropathy. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Taylor & Francis Inc | en_US |
dc.relation.isversionof | 10.1080/08880010701451327 | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | neurotoxicity | en_US |
dc.subject | pyridostigmine | en_US |
dc.subject | pyridoxine | en_US |
dc.subject | vincristine | en_US |
dc.title | Pyridoxine and pyridostigmine treatment in vincristine-induced neuropathy | en_US |
dc.type | article | en_US |
dc.contributor.department | OMÜ | en_US |
dc.identifier.volume | 24 | en_US |
dc.identifier.issue | 05.Aug | en_US |
dc.identifier.startpage | 447 | en_US |
dc.identifier.endpage | 452 | en_US |
dc.relation.journal | Pediatric Hematology and Oncology | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |